Development
AbCellera Biologics Inc.
ABCL
$4.59
$0.092.00%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -57.73% | -207.46% | -349.93% | -123.79% | -149.86% |
| Total Depreciation and Amortization | 30.88% | 10.12% | 20.11% | 43.17% | 43.12% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -31.51% | -9.24% | 25.77% | 1.21% | 91.63% |
| Change in Net Operating Assets | -95.14% | 104.08% | -89.45% | 73.05% | 130.68% |
| Cash from Operations | -163.44% | 99.92% | -92.71% | -143.97% | 284.97% |
| Capital Expenditure | -17.04% | -62.48% | 13.16% | -3.37% | -30.75% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -109.00% | 102.80% | -274.28% | -1,033.59% | -157.15% |
| Cash from Investing | -42.55% | 95.47% | -26.45% | -467.32% | -1,385.03% |
| Total Debt Issued | 1,031.81% | 2,931.17% | -36.75% | -74.76% | 109.55% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -48.80% | -71.14% | 81.31% | -- |
| Cash from Financing | 978.80% | 34,994.74% | -64.28% | 85.37% | -80.97% |
| Foreign Exchange rate Adjustments | 193.41% | 87.57% | 166.03% | -4.41% | 169.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -368.51% | 98.24% | -105.40% | -375.61% | 187.98% |